Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Design Trial With Moxifloxacin as Positive Control in a Nested Crossover to Evaluate the Effects of Multiple Doses of Verducatib (BI 1291583) on Cardiac Safety Parameters in Healthy Male and Female Trial Participants

NCT07760246 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07760246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07760246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Design Trial With Moxifloxacin as Positive Control in a Nested Crossover to Evaluate the Effects of Multiple Doses of Verducatib (BI 1291583) on Cardiac Safety Parameters in Healthy Male and Female Trial Participants
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
August 20, 2026
Completion date
December 30, 2026
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy